[The effects and safety of bortezomib combined with dexamethasone in the treatment of primary systemic amyloidosis].
To evaluate the effects and safety of the regimen of bortezomib combined with dexamethasone (VD) in the treatment of primary systemic (AL) amyloidosis. Five newly diagnosed AL amyloidosis patients confirmed by renal biopsy with a median of 3 organs involved (3 to 5 organs) were treated by VD regimen for 3 (1-4) cycles. Among 3 evaluable patients, 1 was in stable condition and 2 had hematologic response (partial remission and complete remission) and organ function improvement. Hematologic responses were rapid (median 1.5 cycles) and median time to organ response was 2 cycles. Three cases were survived and the periods of follow up were 5, 4 and 4 months respectively. The other 2 died 2 and 14 months after diagnosis. The side effects were asthenia, diarrhea, constipation, edema aggravation and fever, all of which were in I grade. No treatment associating death was found. VD regimen might be an efficient, rapid effective and safe regimen in the treatment of AL amyloidosis.